A recent boom in the marketing and sale of knockoff versions of new, innovative diabetes and anti-obesity medicines is raising serious patient safety concerns.
Vanity Fair recently published an investigation detailing the “wild west” of deceptive telehealth companies and compounding pharmacies who are flooding the market with these knockoffs with disastrous consequences it can have for patients.
Reuters reported that one security firm pulled down 250 websites for selling fake versions of diabetes and anti-obesity medicines. It is difficult to quantify the size of the market as it is not regulated with the same rigor as FDA-approved medicines, but according to Bloomberg the annual demand for compounded weight loss drugs could be more than a $1 billion.
How is this happening?
Rogue actors are taking advantage of a seeming regulatory gray area around drug shortages to make, market and sell lookalike products. In some instances, these entities falsely and dangerously are claiming their products are the same as the FDA-approved innovator medicines.
Importantly, compounded drugs are unapproved by the FDA and not only aren’t the same but are not subject to the same level of oversight. In fact, the FDA has made it clear that compounded products pose a higher risk to patients than FDA approved medicines “because they do not undergo FDA premarket review for safety, effectiveness, or quality.”
The FDA has also provided updated safety information warning that compounded knockoffs often don’t contain the same active ingredients as the FDA-approved medicines.
The Vanity Fair investigation found this opaque industry has become a breeding ground for potentially illegal activity as, “a world of criminals and con artists are filling the void with life-threatening fakes.”
Patients are at risk.
Like the concerns we’ve raised about dangerous importation schemes, subverting FDA-approval standards, and opening our drug supply chain to counterfeit, substandard or diverted, repackaged and adulterated drugs has life-threatening consequences for patients.
The FDA issued an alert to health care providers and patients about the risk of overdoses or dosing errors with the use of compounded knockoffs.
Late last year U.S. regulators seized batches of counterfeit and knockoff diabetes and anti-obesity medicines that had made it into the legitimate pharmaceutical supply chain.
The National Association of Boards of Pharmacy (NABP), an organization that works to help support patients and prescription drug safety, issued a report arguing bad actors are taking advantage of patients and putting them at risk.
To make matters worse, patients often don’t know they are being sold knockoff versions the brand diabetes and anti-obesity medicines.
Bloomberg recently interviewed a South Carolina mother who found a telehealth company that offered compounded versions of weight loss drugs. Her experience with the drug varied between doses – sometimes it worked, sometimes she had a negative reaction and in one instance the drug had no effect at all. What was most concerning was the inconsistency.
The Vanity Fair investigation found 352 adverse events reported to the FDA submitted by patients and providers. “Four people died, and many others suffered life-threatening reactions.”
The NABP report highlights other examples, including three Americans being hospitalized last year after using suspected counterfeits.
Moreover, the World Health Organization issued a new global warning last month, stating:
“These falsified products could have harmful effects to people’s health; if the products don’t have the necessary raw components, falsified medicines can lead to health complications resulting from unmanaged blood glucose levels or weight. In other cases, another undeclared active ingredient may be contained in the injection device, e.g., insulin, leading to an unpredictable range of health risks or complications.”
The companies that make the FDA-approved, innovative medicines are working to inform the public about the safety risks and to hold bad actors accountable.
Despite mounting evidence that this opaque market is putting patients' health and safety at risk, the compounding industry and rogue actors have largely been given a free pass. This issue desperately needs more oversight from lawmakers and regulators and bad actors need to be held accountable.
Nick McGee
Nick McGee is deputy vice president, public affairs, at PhRMA focusing on communications strategies and activities for the organization’s advocacy priorities.
Nick McGee
Mass compounding puts patients at risk
Advancing patient care: A look at new medicines approved in 2025
Knockoffs of FDA-approved drugs put patients at risk
PDUFA: Essential to America’s edge in drug development and patient access
CMS, don’t fall behind the rest of the medical community on obesity
Major drug compounder is spending millions on misleading Super Bowl ad
New Report: Tackling chronic conditions with preventive treatment
ICYMI: Misaligned policies undermine patient access
The use of real-world data in drug development
Critics repeat same, misleading narrative on potential “costs” of new medicines
New analysis: Accelerated approval pathway is changing lives in underserved communities
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
Florida’s importation plan puts patients in danger
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
Taking stock of obesity and its costly effects
Decentralized clinical trials and the future of drug development
How FDA’s modernization strategy could improve drug development
Setting the record straight on accelerated approval
FDA should remain the authority on the safety and effectiveness of medicines
What you should know about real-world evidence and drug development
Three things to know about the accelerated approval pathway
PDUFA and BsUFA reauthorizations are wins for patients
Word of the Month: Biomarkers and surrogate endpoints
Why drug importation is bad for Americans
Ensuring timely reauthorization of PDUFA and BsUFA
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
The importance of timely PDUFA and BsUFA reauthorization
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition
Meeting Tomorrow: Looking ahead to PDUFA VII
The impact of monoclonal antibodies and COVID-19 recovery
PDUFA VII is critical for future biopharmaceutical innovation and for patients
How strengthening the biosimilar marketplace benefits patients
The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Nearly 400 cell and gene therapies in development to target a broad range of diseases
PhRMA submits comments on FDA’s proposed rule on drug importation
Drug importation: An old idea that is still a bad idea
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
What they’re saying: Safety is top concern for recent drug importation proposal
ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals
PhRMA responds to Florida’s request for information on drug importation
Guest Post: Using the patient voice to go boldly
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
PhRMA CEO raises concerns with Florida importation proposal, highlights reforms needed to lower costs for patients
Guest post: Hearing from patients on Rare Disease Day
Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation
Look at the facts. Drug importation is dangerous.
Why state drug importation pilot programs don’t work
Putting 2018 medicine approvals in context
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
Balancing innovation and competition in the biologics marketplace
New analysis shows that more medicines worldwide are available to U.S. patients
Securely dispose of your unwanted medicines on National Take Back Day
Spending on medicines grew less than one percent in 2017
Rare Disease Day: Unmet need inspires innovation
Innovation comes in many forms, including new and expanded uses of existing medicines
ICYMI: Why 2017 medicine approvals matter
New surveys find payers and providers want more data from biopharmaceutical companies
Supporting opportunities for enhanced competition in the marketplace
The Washington Post retracts PhRMA claim in opioid story
PhRMA response to Washington Post and 60 Minutes stories
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Protect your health: Important disaster preparedness tips for Harvey and Irma
PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis
Opportunities to build upon enhanced competition for medicines in the marketplace
Why reauthorization of PDUFA matters
A critical opportunity to prevent prescription drug abuse
Former law enforcement officials raise concerns with drug importation proposals
Resources for understanding the dangers of drug importation
Guest Post: The importance of a modern FDA in drug discovery
How drug importation schemes could increase U.S. law enforcement burdens
Case Study: How one online pharmacy knowingly endangered U.S. consumers
Why drug importation threatens patient safety
Fact Check Friday: The truth about drug importation and patient safety
What you don’t know about importation from Canada
Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
More oversight needed of unapproved medicines that threaten patients’ health
Obesity
FDA
Prescription Drug Safety
More oversight needed of unapproved medicines that threaten patients’ health
More oversight needed of unapproved medicines that threaten patients’ health